Relationship of target concentrations with efficacy: results from the apex-1 study of bcx7353
Hereditary angioedema (HAE) is characterized by unpredictable attacks of debilitating swelling. APeX-1 was a Phase 2, double-blind, placebo-controlled study to evaluate the prevention of attacks with BCX7353, a once daily oral kallikrein inhibitor, in patients with HAE.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: H. Farkas, E. Aygoren-Pursun, V. Grivcheva Panovska, A. Huissoon, T. Kinaciyan, S. Murray, M. Cornpropst, W. Sheridan, M. Maurer, M. Cicardi Tags: P157 Source Type: research